On June 14th, OBIO hosted Dr. Yuan Fang (VP Regulatory Affairs, Quality and Manufacturing; Focal Healthcare Inc.) who spoke about his perspective on the recent changes at the U.S. Food and Drug Administration (FDA).
Springboard is recruiting women-led digital health companies to join their 2018 Health Innovation Hub cohort to help those seeking growth funding accelerate through an inflection point of growth.
CellAegis completed its patient enrollment in a large-scale, UK investigator-sponsored trial to further assess the efficacy of remote ischemic conditioning in reducing clinical events in patients presenting with STEMI in patients receiving treatment in hospital catheterization labs or emergency rooms.
Ontario's Ministry of International Trade, is organizing a Trade Mission to the RESI Conference, September 6, 2018, Boston Marriott Copley Place Hotel. This Trade Mission will be able to accommodate a maximum of ten Ontario companies.
During his lively and highly engaging presentation on June 12, ‘Strategic Marketing & Commercialization Plans for Early Stage Companies,’ Dr. Brian Jahns (Senior VP, Commercial and Business Development at Trillium Therapeutics Inc) discussed approaches for developing strategies and the importance of scenario planning.
Executives from Ontario’s healthcare sector say they could benefit from a network of early adopter institutions and a capital fund that invests directly in health science companies preparing to commercialize their products and market them globally as they scale their businesses in Canada.
If you missed the Medical Device Playbook hosted by StarFish Medical and OBIO, you can still watch Starfish CEO Scott Phillips' presentation titled "Dream a Bigger Dream".
Radialis Medical won the Thunder Bay PITCH competition co-hosted by Northern Ontario Angels (NOA) and the Northern Ontario Innovation Centre (NOIC). Competitors' pitches were made to a panel of angel investors who voted on the best pitch.
On June 14th, get behind-the-scenes on the recent changes at the FDA and learn more about how regulatory process changes affect your company.
OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 11 high-potential health companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing.